Dr. Zumsteg specializes in the treatment of head and neck, and genitourinary cancers. In addition to his clinical practice, he is actively engaged in research spanning epidemiology, health services, clinical trials and translational applications. Through this work, Dr. Zumsteg has developed a novel risk stratification system for patients with intermediate risk prostate cancer that is currently widely used by oncologists in clinical practice and cited in National Comprehensive Cancer Network Guidelines. Additionally, he has helped identify changing epidemiologic patterns and studied novel therapeutic paradigms for head and neck cancers arising in older adults. He is the author of numerous peer reviewed publications, with articles appearing in journals such as Lancet Oncology, Journal of Clinical Oncology, JAMA Oncology, European Urology, Clinical Cancer Research, Cancer, and the International Journal of Radiation Oncology, Biology and Physics. Dr. Zumsteg's research program attempts to bridge epidemiology, clinical outcomes, and biology, thereby utilizing tumor, and patient, associated factors to optimize personalization of treatment for head and neck and genitourinary cancers.